1. Johnson & Johnson (NYSE:JNJ)
Number of Hedge Fund Holders — 117
Oncology Growth Gives the Healthcare Giant More Than a Defensive Story
Johnson & Johnson (NYSE: JNJ) leads this ranking with an oncology business already generating substantial revenue across several treatment categories. Third-quarter cancer medicine sales reached approximately $7.6 billion, up 16.4% on a reported basis, according to its October 13 financial release. Darzalex contributed approximately $4.24 billion, increasing 15.4%, while Carvykti revenue rose 35.5% to $710 million. These figures give investors exposure to an established cancer treatment franchise rather than a business dependent on a single experimental medicine. They also demonstrate why oncology deserves a prominent place in assessing the company’s longer-term growth prospects.
Expansion extended across other products. Tecvayli revenue increased 76.6% to $312 million, while combined Rybrevant and Lazcluze sales rose 62.3% to $320 million. The portfolio therefore spans multiple approaches, including cell therapy, bispecific antibodies, and treatments directed at specific cancer biology. Chief Executive Officer Joaquin Duato referred to “the accelerating momentum of our focused portfolio” in the quarterly announcement. For investors comparing large-cap oncology stocks, having several commercial products creates more ways to generate growth. It also requires close examination of manufacturing capacity, treatment-center access, competitive positioning, and the evidence supporting use across different stages of disease.
The wider financial picture deserves equal attention. Total quarterly sales increased 5.9% to approximately $25.4 billion, but reported earnings of $0.09 per share reflected major special charges and transaction-related effects. Adjusted earnings were $2.59 per share. This gap illustrates why investors should examine both reported and adjusted results when assessing healthcare stocks with litigation and acquisition exposure. The oncology business provides a strong commercial foundation, but shareholders also own the financial obligations and operating demands of the broader group. A diversified portfolio can make growth more resilient; the price paid still determines how much of that progress reaches the investor.
Ranking rationale — Johnson & Johnson (NYSE: JNJ) ranks first with 117 hedge fund holders, the highest count in the supplied dataset. Its sizable oncology revenue base, multiple growing cancer medicines, and broader diversification support the position, while valuation, litigation-related costs, and continued commercial execution remain material considerations.
YOU MUST READ THIS: 10 Best Biotech Stocks to Buy According to Billionaires.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
